Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment
about
Current and developing synthetic pharmacotherapy for treating relapsed/refractory multiple myeloma.The proteasome and proteasome inhibitors in multiple myeloma.Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPInterpreting clinical trial data in multiple myeloma: translating findings to the real-world setting
P2860
Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment
description
2017 nî lūn-bûn
@nan
2017 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2017 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
name
Carfilzomib-lenalidomide-dexam ...... myeloma by previous treatment
@ast
Carfilzomib-lenalidomide-dexam ...... myeloma by previous treatment
@en
type
label
Carfilzomib-lenalidomide-dexam ...... myeloma by previous treatment
@ast
Carfilzomib-lenalidomide-dexam ...... myeloma by previous treatment
@en
prefLabel
Carfilzomib-lenalidomide-dexam ...... myeloma by previous treatment
@ast
Carfilzomib-lenalidomide-dexam ...... myeloma by previous treatment
@en
P2093
P2860
P50
P356
P1433
P1476
Carfilzomib-lenalidomide-dexam ...... myeloma by previous treatment
@en
P2093
A Jakubowiak
A K Stewart
G G Mihaylov
M A Dimopoulos
P2860
P2888
P356
10.1038/BCJ.2017.31
P577
2017-04-21T00:00:00Z
P6179
1085006967